BROADCASTS.com

b'Michael Weiss explains TG Therapeutics cancer drugs with expected PDUFA dates. He says they have a\\xa0multiple sclerosis drug with a target approval for mid-year 2022. He says their R&D expense has come down and they have $600 million in cash as of the end of the year.'